Physician profile
Ashfaque Unwala
NPI 1861447260
$1,665.83
in general payments reported to CMS, 2019-2025
24 companies · $336 in 2025
The $336 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $65.45 · 2021: $142 · 2022: $245 · 2023: $299 · 2024: $416 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,051.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $323.57 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $293.49 | 2019-2025 | |
| Medtronic, INC. | $172.39 | 2022-2024 | Linq II |
| Abiomed | $152.99 | 2021-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $115.82 | 2023-2024 | Eliquis, Camzyos |
| Boston Scientific Corporation | $54.75 | 2019 | |
| Penumbra, INC. | $50.87 | 2021-2025 | Indigo System |
| Astrazeneca Pharmaceuticals LP | $48.87 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $46.73 | 2021-2023 | Venclose Maven Catheter |
| Abbott Laboratories | $46.17 | 2025 | Triclip, Aveir |
| Merck Sharp & Dohme LLC | $46.03 | 2022-2024 | Verquvo |
| Terumo Medical Corporation | $35.31 | 2019-2021 | |
| Stryker Corporation | $33.48 | 2019-2025 | Flowtriever |
| Alnylam Pharmaceuticals INC. | $32.65 | 2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $29.01 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $28.84 | 2019 | |
| Irhythm Technologies, INC. | $28.12 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.00 | 2025 | |
| W. L. Gore & Associates, INC. | $18.96 | 2022 | |
| Novo Nordisk INC | $18.31 | 2025 | Ozempic |
| Cardinal Health 200 LLC | $17.93 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.90 | 2023 | Evkeeza |
| Amgen INC. | $16.97 | 2023 | Repatha |
| Chiesi USA, INC. | $16.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashfaque Unwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.